|
MechanismABCG2 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants
A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants.
100 Clinical Results associated with Portal Therapeutics, Inc.
0 Patents (Medical) associated with Portal Therapeutics, Inc.
100 Deals associated with Portal Therapeutics, Inc.
100 Translational Medicine associated with Portal Therapeutics, Inc.